2025 India Adenovirus Vaccine Market Revenue Opportunities Report
Description
The 2025 India Adenovirus Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adenovirus Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the adenovirus vaccine market in India include Bharat Biotech, Serum Institute of India (SII), Cadila Healthcare, and GlaxoSmithKline (GSK). Bharat Biotech is a major player with its indigenous adenoviral-based COVID-19 vaccine candidate BBV154 (ChAd-SARS-CoV-2), which is in advanced clinical trials with intranasal delivery offering sterilizing immunity. Bharat Biotech also partners internationally for novel adenovirus vaccine technologies and holds extensive manufacturing capabilities supporting large-scale production. Serum Institute of India is the world’s largest vaccine manufacturer, producing the adenovirus vector-based Covishield vaccine and engaging in key global and local vaccine initiatives, supplying to over 170 countries and expanding adenoviral vaccine production capacity.
Cadila Healthcare developed the DNA plasmid vaccine ZyCoV-D and has advanced trials for adenoviral vaccines, with production underway targeting emergency use approvals. GlaxoSmithKline, a leading multinational with strong vaccine portfolios including viral vaccines, operates extensively in India to provide advanced vaccines broadly across pediatric and adult segments in partnership with local agencies. These companies combine innovation, government collaborations, and robust manufacturing to drive the adenovirus vaccine segment in India's fast-growing immunization market, projected to expand at a CAGR of approximately 8.5% to 2033.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Adenovirus Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the adenovirus vaccine market in India include Bharat Biotech, Serum Institute of India (SII), Cadila Healthcare, and GlaxoSmithKline (GSK). Bharat Biotech is a major player with its indigenous adenoviral-based COVID-19 vaccine candidate BBV154 (ChAd-SARS-CoV-2), which is in advanced clinical trials with intranasal delivery offering sterilizing immunity. Bharat Biotech also partners internationally for novel adenovirus vaccine technologies and holds extensive manufacturing capabilities supporting large-scale production. Serum Institute of India is the world’s largest vaccine manufacturer, producing the adenovirus vector-based Covishield vaccine and engaging in key global and local vaccine initiatives, supplying to over 170 countries and expanding adenoviral vaccine production capacity.
Cadila Healthcare developed the DNA plasmid vaccine ZyCoV-D and has advanced trials for adenoviral vaccines, with production underway targeting emergency use approvals. GlaxoSmithKline, a leading multinational with strong vaccine portfolios including viral vaccines, operates extensively in India to provide advanced vaccines broadly across pediatric and adult segments in partnership with local agencies. These companies combine innovation, government collaborations, and robust manufacturing to drive the adenovirus vaccine segment in India's fast-growing immunization market, projected to expand at a CAGR of approximately 8.5% to 2033.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
